Phibro Animal Health acquires Zoetis' medicated feed additive portfolio for $350M

PHIBRO ANIMAL HEALTH CORP

$350M cash purchase; acquired portfolio generated ~$400M revenue in 2023 across 37 product lines.
Six manufacturing sites (four US, one Italy, one China) and >300 Zoetis employees expected to transition.
Deal expected to close H2 2024; Phibro to fund primarily with debt, targeting net leverage 3.5-4.0x at close.
Phibro expects acquisition to boost EBITDA margin and be accretive to adjusted EPS.
Combined pro forma sales ~$1.4B in last twelve months.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PHIBRO ANIMAL HEALTH CORP entered into Purchase and Sale Agreement with Zoetis Inc. valued at $350 million (effective 2024-04-28).

Action: entry
Agreement: asset purchase
Counterparty: Zoetis Inc.
Value: $350 million
Effective: 2024-04-28

Exact text from the filing

On April 28, 2024, Phibro Animal Health Corporation, a Delaware corporation (“Phibro Animal Health”), and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of Phibro Animal Health (together with Phibro Animal Health, “Phibro”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PHIBRO ANIMAL HEALTH CORP entered into Debt Commitment Letter with Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A. valued at $325 million senior secured incremental first lien term loan facility (effective 2024-04-28).

Action: entry
Agreement: credit facility
Counterparty: Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A.
Value: $325 million senior secured incremental first lien term loan facility
Effective: 2024-04-28

Exact text from the filing

Phibro entered into a debt commitment letter (the “Commitment Letter”), dated as of April 28, 2024, with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), Compeer Financial, PCA (“Compeer”) and Citibank, N.A. (“Citibank” and, collectively with Rabobank and Compeer, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325 million (the “Incremental Term Facility”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-24-053265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.